Literature DB >> 23943403

Reproducibility of positive results for the detection of serum galactomannan by Platelia™ aspergillus EIA.

Kelly C M C Pedroza1, Sócrates B de Matos, Daniel L de Moura, Mônica B B Oliveira, Marco A S Araújo, Roberto J M Nascimento, Fernanda W M Lima.   

Abstract

Galactomannan (GM) was recently included in consensus guidelines as an indirect mycological criterion for the diagnosis of invasive aspergillosis. Currently, there is an enzyme immunoassay available to detect GM in biological samples, the Platelia™ Aspergillus EIA. In this study, the reproducibility of positive results obtained using this assay was evaluated using serum samples from neutropenic patients. A trend toward lower values was observed, and 55 %(27/49) of positive results were negative after retesting. A low reproducibility of positive results for the detection of GM in serum was observed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23943403     DOI： 10.1007/s11046-013-9670-z

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   2.574


  11 in total

Review 1.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.

Authors:  Monique A S H Mennink-Kersten; J Peter Donnelly; Paul E Verweij
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

2.  Response to: lack of intra-laboratory reproducibility in using Platelia Aspergillus enzyme immunoassay test for detection of Aspergillus galactomannan antigen.

Authors:  A Bizzini; O Marchetti; P Meylan
Journal:  Transpl Infect Dis       Date:  2011-12-20       Impact factor: 2.228

3.  Galactomannan: testing the same sample twice?

Authors:  E Furfaro; M Mikulska; F Miletich; C Viscoli
Journal:  Transpl Infect Dis       Date:  2012-04-08       Impact factor: 2.228

4.  Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies.

Authors:  Marcio Nucci; Simone Aranha Nouér; Monica Grazziutti; Naveen Sanath Kumar; Bart Barlogie; Elias Anaissie
Journal:  Clin Infect Dis       Date:  2010-10-29       Impact factor: 9.079

5.  Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay.

Authors:  Johan A Maertens; Rocus Klont; Christine Masson; Koen Theunissen; Wouter Meersseman; Katrien Lagrou; Christine Heinen; Brigitte Crépin; Johan Van Eldere; Marc Tabouret; J Peter Donnelly; Paul E Verweij
Journal:  Clin Infect Dis       Date:  2007-04-04       Impact factor: 9.079

6.  Lack of intra-laboratory reproducibility in using Platelia Aspergillus enzyme immunoassay test for detection of Aspergillus galactomannan antigen.

Authors:  I Oren; I Avidor; H Sprecher
Journal:  Transpl Infect Dis       Date:  2011-07-06       Impact factor: 2.228

7.  Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance.

Authors:  Zdenek Racil; Iva Kocmanova; Martina Toskova; Lucie Buresova; Barbora Weinbergerova; Martina Lengerova; Monika Rolencova; Jana Winterova; Kristyna Hrncirova; Pavlina Volfova; Jana Skrickova; Jiri Mayer
Journal:  Int J Infect Dis       Date:  2011-10-30       Impact factor: 3.623

8.  Clinical utility and prognostic value of galactomannan in neutropenic patients with invasive aspergillosis.

Authors:  I Hadrich; F Makni; F Cheikhrouhou; S Neji; I Amouri; H Sellami; H Trabelsi; H Bellaaj; M Elloumi; A Ayadi
Journal:  Pathol Biol (Paris)       Date:  2011-12-10

9.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 10.  Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis.

Authors:  Valério R Aquino; Luciano Z Goldani; Alesssandro C Pasqualotto
Journal:  Mycopathologia       Date:  2007-04-05       Impact factor: 3.785
View more
  4 in total

1.  Improved Standardization of the Bio-Rad Platelia Aspergillus Galactomannan Antigen Sandwich Enzyme Immunoassay Using the DS2 (Dynex) Enzyme-Linked Immunosorbent Assay (ELISA) Processing System.

Authors:  R L Gorton; P L White; E Bagkeris; D Cotterall; R Desai; T McHugh; C C Kibbler
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

2.  Insufficient demonstration of long-term stability of Aspergillus galactomannan.

Authors:  Gemma L Johnson; Shah-Jalal Sarker; Stephen A Bustin; Samir G Agrawal
Journal:  J Clin Microbiol       Date:  2014-11       Impact factor: 5.948

3.  Importance of operational factors in the reproducibility of Aspergillus galactomannan enzyme immune assay.

Authors:  Nicolas Guigue; Samuel Lardeux; Alexandre Alanio; Samia Hamane; Marc Tabouret; Stéphane Bretagne
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

4.  Galactomannan Downregulates the Inflammation Responses in Human Macrophages via NFκB2/p100.

Authors:  Víctor Toledano; Enrique Hernández-Jiménez; Carolina Cubillos-Zapata; Marta Flandez; Enrique Álvarez; Aníbal Varela-Serrano; Ramón Cantero; Gema Valles; Francisco García-Rio; Eduardo López-Collazo
Journal:  Mediators Inflamm       Date:  2015-09-09       Impact factor: 4.711
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.